Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Apyx Medical (APYX) EBIAT (2016 - 2025)

Apyx Medical's EBIAT history spans 16 years, with the latest figure at -$1.3 million for Q4 2025.

  • For Q4 2025, EBIAT rose 70.5% year-over-year to -$1.3 million; the TTM value through Dec 2025 reached -$11.2 million, up 52.18%, while the annual FY2025 figure was -$11.2 million, 52.22% up from the prior year.
  • EBIAT reached -$1.3 million in Q4 2025 per APYX's latest filing, up from -$2.0 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$1.0 million in Q2 2023 to a low of -$9.6 million in Q4 2023.
  • Average EBIAT over 5 years is -$4.6 million, with a median of -$4.6 million recorded in 2023.
  • Peak YoY movement for EBIAT: surged 81.3% in 2023, then crashed 546.32% in 2024.
  • A 5-year view of EBIAT shows it stood at -$2.0 million in 2021, then crashed by 197.83% to -$6.0 million in 2022, then plummeted by 58.82% to -$9.6 million in 2023, then soared by 52.5% to -$4.6 million in 2024, then soared by 70.5% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's EBIAT are -$1.3 million (Q4 2025), -$2.0 million (Q3 2025), and -$3.7 million (Q2 2025).